
Clear Scientific Reports Success in Phase 2 Fentanyl Removal Trial
A Cambridge-based biotech, Clear Scientific, has successfully completed a Phase 2 trial for CS-1103, an investigational therapy designed to physically bind and remove fentanyl from the human body. The results show a 25-fold increase in fentanyl excretion, offering a potential breakthrough in treating synthetic opioid overdoses.



























